购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空

Lapatinib

Rating icon 很棒
产品编号 T0078Cas号 231277-92-2
别名 拉帕替尼, GW572016, GSK572016

Lapatinib (GW572016) 是一种 ErbB2 和 EGFR 的抑制剂 (IC50=9.2/10.8 nM),具有口服活性。Lapatinib 具有抗肿瘤活性,可以用于治疗 HER2 过表达的晚期或转移性乳腺癌。

Lapatinib

Lapatinib

Rating icon 很棒
纯度: 99.89%
产品编号 T0078 别名 拉帕替尼, GW572016, GSK572016Cas号 231277-92-2

Lapatinib (GW572016) 是一种 ErbB2 和 EGFR 的抑制剂 (IC50=9.2/10.8 nM),具有口服活性。Lapatinib 具有抗肿瘤活性,可以用于治疗 HER2 过表达的晚期或转移性乳腺癌。

规格价格库存数量
10 mg¥ 197现货
25 mg¥ 318现货
50 mg¥ 453现货
100 mg¥ 656现货
200 mg¥ 958现货
500 mg¥ 1,580现货
1 mL x 10 mM (in DMSO)¥ 243现货
大包装 & 定制
加入购物车
实验操作小课堂
查看更多

"Lapatinib"的相关化合物库

选择批次:
纯度:99.89%
联系我们获取更多批次信息
TargetMol 的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。

产品介绍

生物活性
产品描述
Lapatinib (GW572016) is an inhibitor of ErbB2 and EGFR (IC50=9.2/10.8 nM) with oral activity. Lapatinib has antitumor activity and can be used to treat advanced or metastatic breast cancer with HER2 overexpression.
靶点活性
ErbB2:9.2 nM (cell free), EGFR:10.8 nM (cell free)
体外活性
方法:14 株人胃癌和食管癌细胞系用 Lapatinib (0.3125-10 µmol/L) 处理 6 天,使用 particle counter 检测细胞数。
结果:N87、OE19、NUGC4、NUGC3、FU97、SNU16 细胞对 Lapatinib 敏感,IC50 分别为 0.01、0.09、0.35、2.24、4.86、8.58 μmol/L。[1]
方法:人乳腺癌细胞 MDA-MB-231 和 SK-BR-3 用 Lapatinib (0.5-2 µM) 处理 48 h,使用 Western Blot 方法检测靶点蛋白表达水平。
结果:与较低浓度相比,用 1.0 μM Lapatinib 处理的 MDA-MB-231 和 SK-BR-3 细胞系中 PKM2 的表达均显著降低。[2]
体内活性
方法:为检测体内抗肿瘤活性,将 Lapatinib (100 mg/kg) 腹腔注射给携带人胃癌肿瘤 N87 的 CD-1 athymic nude 小鼠,每天一次,持续三周。
结果:Lapatinib 导致 N87 异种移植物的肿瘤消退。[1]
方法:为检测体内抗肿瘤活性,将 Lapatinib (30-100 mg/kg,灌胃给药,每天两次持续二十一天) 和 Topoteca (6-10 mg/kg,腹腔注射,每四天一次持续三次) 灌胃给药给携带人乳腺癌肿瘤 BT474 的 SCID 小鼠。
结果:Lapatinib 和 Topoteca 组合在 ER2+BT474 异种移植物中显示出增强的功效。[3]
激酶实验
The IC50 values for inhibition of enzyme activity are generated by measuring the inhibition of phosphorylation of a peptide substrate. The intracellular kinase domains of EGFR and ErbB2 are purified from a baculovirus expression system. EGFR and ErbB2 reactions are performed in 96-well polystyrene round-bottomed plates in a final volume of 45 μL. Reaction mixtures contain 50 mM 4-morpholinepropanesulfonic acid (pH 7.5), 2 mM MnCl2, 10 μM ATP, 1 μCi of [γ33P] ATP/reaction, 50 μM Peptide A [Biotin-(amino hexonoic acid)-EEEEYFELVAKKK-CONH2], 1 mM dithiothreitol, and 1 μL of DMSO containing serial dilutions of Lapatinib beginning at 10 μM. The reaction is initiated by adding the indicated purified type-1 receptor intracellular domain. The amount of enzyme added is 1 pmol/reaction (20 nM). Reactions are terminated after 10 minutes at 23°C by adding 45 μL of 0.5% phosphoric acid in water. The terminated reaction mix (75 μL) is transferred to phosphocellulose filter plates. The plates are filtered and washed three times with 200 μL of 0.5% phosphoric acid. Scintillation cocktail (50 μL) is added to each well, and the assay is quantified by counting in a Packard Topcount. IC50 values are generated from 10-point dose-response curves [1].
细胞实验
Cells are plated in 96-well plates, in the media, at the following densities: HFF and HN5, 1000 cells/well and BT474, 5000 cells/well. After 24 h, the cells are exposed to vehicle (0.3% DMSO) or Lapatinib (1 nM, 10 nM, 100 nM, 1μM, 10μM, and 100μM). Lapatinib is removed from the cells after 72 h and is replaced by either DMEM containing 10% FBS and 50 μg/mL Gentamicin (HFF and HN5) or RPMI containing 10% FBS and 50 μg/mL Gentamicin (BT474). Methylene blue staining is performed at the time points over a total period of 16 days. Relative cell number is estimated using methylene blue staining. The absorbance at 620 nm is read in a Spectra microplate reader. Cell death and cell cycle analysis are assessed by propidium iodide staining and antibody detection of incorporated BrdUrd and staining with propidium iodide [1].
动物实验
CD-1 nude female mice are used for HN5 human tumor xenografts, which are initiated by injection of a cell suspension in PBS: Matrigel (1:1). C.B-17 SCID female mice are used for BT474 human tumor xenografts, which are initiated by implantation of tumor fragments (20-100 mg) from established tumors. Tumor cells and fragments are implanted by s.c. injection in the right flank. The s.c. tumors are measured with calipers, and mice are weighed twice weekly. Tumor weight is estimated from tumor volume using this formula: length×width2/2=tumor volume (mm3). Treatment begins when tumors are palpable, 3-5 mm in diameter. Lapatinib (30 and 100 mg/kg) is administered p.o. twice daily for 21 days in a vehicle of sulfo-butyl-ether-β-cyclodextrin 10% aqueous solution (CD10) [1].
别名拉帕替尼, GW572016, GSK572016
化学信息
分子量581.06
分子式C29H26ClFN4O4S
CAS No.231277-92-2
SmilesN(C=1C2=C(C=CC(=C2)C=3OC(CNCCS(C)(=O)=O)=CC3)N=CN1)C4=CC(Cl)=C(OCC5=CC(F)=CC=C5)C=C4
密度1.381 g/cm3 (Predicted)
储存&溶解度
存储Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度信息
DMSO: 18.33 mg/mL (31.55 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 9.3 mg/mL (16.01 mM), Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately.
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
溶液配制表
1mg5mg10mg50mg
1 mM1.7210 mL8.6050 mL17.2099 mL86.0496 mL
5 mM0.3442 mL1.7210 mL3.4420 mL17.2099 mL
10 mM0.1721 mL0.8605 mL1.7210 mL8.6050 mL
1mg5mg10mg50mg
20 mM0.0860 mL0.4302 mL0.8605 mL4.3025 mL

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
TargetMol | Animal experiments比如您的给药剂量是 10 mg/kg ,每只动物体重 20 g ,给药体积 100 μLTargetMol | Animal experiments 一共给药动物 10 只 ,您使用的配方为 5% TargetMol | reagent DMSO+ 30%PEG300+ 5%Tween 80 + 60% ddH2O. 那么您的工作液浓度为 2 mg/mL
母液配置方法: 2 mg 药物溶于 50 μLDMSOTargetMol | reagent ( 母液浓度为 40 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:50μLDMSOTargetMol | reagent 母液,添加 300 μLPEG300TargetMol | reagent 混匀澄清,再加 50μLTween 80, 混匀澄清,再加 600μLddH2OTargetMol | reagent 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
%Tween 80
%ddH2O

剂量转换

对于不同动物的给药剂量换算,您也可以参考 更多

关键词

评论列表

4个月前
5.0
Rating icon 很棒

评论内容

Related Tags: buy Lapatinib | purchase Lapatinib | Lapatinib cost | order Lapatinib | Lapatinib chemical structure | Lapatinib in vivo | Lapatinib in vitro | Lapatinib formula | Lapatinib molecular weight